Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: TAT-modified serum albumin nanoparticles for sustained-release of tetramethylpyrazine and improved targeting to spinal cord injury

Fig. 4

Cytotoxicity assessment after different treatments. Cell viability of BV2 after incubation with different formulations of nanoparticles for 24 h (a), 48 h (c), 72 h (e) and the same operations on SHSH-SY5Y for 24 h (b), 48 h (d), 72 h (f). Data from CCK8 assay were expressed as mean ± standard deviation (n = 5). ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) was used to assess the statistical differences between groups. Symbols represented statistical significance of the labeled groups with group of TMP.HCl (#P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001)

Back to article page